Literature DB >> 29991452

Challenges for pulmonary delivery of high powder doses.

Imco Sibum1, Paul Hagedoorn2, Anne Haaije de Boer2, Henderik Willem Frijlink2, Floris Grasmeijer2.   

Abstract

In recent years there is an increasing interest in the pulmonary delivery of large cohesive powder doses, i.e. drugs with a low potency such as antibiotics or drugs with a high potency that need a substantial fraction of excipient(s) such as vaccines stabilized in sugar glasses. The pulmonary delivery of high powder doses comes with unique challenges. For low potency drugs, the use of excipients should be minimized to limit the powder mass to be inhaled as much as possible. To achieve this objective the inhaler design should be adapted to the properties of the API in order to achieve a compatible combination of the drug formulation and inhaler device. The inhaler should have an appropriate powder dosing principle for which prefilled compartments seem most appropriate. The drug formulation should not only allow for accurate filling of these compartments but also enable efficient compartment emptying during inhalation. The dispersion principle must have the capacity to disperse considerable amounts of powder in a short time frame that allows the powder to reach the deep lung. Last, but not least, the inhaler should be simple and intuitive in use, be cost-effective and exhibit accurate and consistent, preferably patient independent, pulmonary delivery performance.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug formulation; Dry powder inhaler; High dose pulmonary delivery; Inhalation; Inhaler design

Mesh:

Substances:

Year:  2018        PMID: 29991452     DOI: 10.1016/j.ijpharm.2018.07.008

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

2.  Effect of inflow conditioning for dry powder inhalers.

Authors:  Gajendra Singh; Albyn Lowe; Athiya Azeem; Shaokoon Cheng; Hak-Kim Chan; Ross Walenga; Agisilaos Kourmatzis
Journal:  Int J Pharm       Date:  2021-09-08       Impact factor: 5.875

Review 3.  Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones.

Authors:  Julien Brillault; Frédéric Tewes
Journal:  Pharmaceutics       Date:  2020-04-23       Impact factor: 6.321

Review 4.  Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications.

Authors:  Zhanying Zheng; Sharon Shui Yee Leung; Raghvendra Gupta
Journal:  Pharmaceutics       Date:  2021-02-01       Impact factor: 6.321

Review 5.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

6.  Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice.

Authors:  Changjiao Gan; Wenbo Luo; Yunzhou Yu; Zhouguang Jiao; Sha Li; Duo Su; Junxia Feng; Xiaodong Zhao; Yefeng Qiu; Lingfei Hu; Dongsheng Zhou; Xiaolu Xiong; Jinglin Wang; Huiying Yang
Journal:  NPJ Vaccines       Date:  2021-06-22       Impact factor: 7.344

7.  Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine.

Authors:  Imco Sibum; Paul Hagedoorn; Markus P G Kluitman; Martijn Kloezen; Henderik W Frijlink; Floris Grasmeijer
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.